CTLA4 and neoplasm: Second, the therapeutic immune checkpoint blockade of CTLA-4 or PDL1/PD1 reinvigorates exhausted tumor-infiltrating lymphocytes (TILs) and has anti-tumor effects in a subset of patients [5].